anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention concerns methods and compositions comprising an anti-IGF-1R antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer. The anti-IGF-1R antibody or fragment may be part of a complex, such as a DOCK-AND-LOCK™ (DNL™) (complex produced by binding interaction between anchor domain moiety of A-kinase anchoring protein and dimerization and docking domain moiety of protein kinase A regulatory subunit) complex. Preferably, the DNL™ (complex produced by binding interaction between anchor domain moiety of A-kinase anchoring protein and dimerization and docking domain moiety of protein kinase A regulatory subunit) complex also comprises a second antibody, a second antibody fragment, an affibody or a cytokine. More preferably, the cytokine is interferon-α2b. Most preferably, the second antibody, second fragment or affibody binds to IGF-1R, TROP2 or CEACAM6. The anti-IGF-1R antibody or complex may be administered alone or in combination with a therapeutic agent, such as an mTOR inhibitor.
Understanding the cause of Heart Failure (HF) and how the body will respond to it, is critical for an effective treatment. HF is a global problem with significant morbidity and mortality, despite improved understanding of the pathophysiology and a growing range of therapeutic options. Jordanian Heart Failure Registry (JoHFR) will be the first research project of heart failure prevalence in Jordan. It is undertaken by primary healthcare professionals with main aim to improve knowledge about the care of patients with HF. The investigators responsible for conducting this research are physicians and their teams who deal with heart failure patients in their outpatient and inpatient clinic centers including the public and private medical sectors in Jordan's medical community. Standards in the Hashemite kingdom of Jordan complies with the recognized good guideline directed medical practices internationally
BACKGROUND/OBJECTIVES: The infant diet represents one of the main modifiable determinants of early growth. This study aimed to investigate the associations of infant feeding practices with body mass index (BMI) until 7.5 years.
SUBJECTS/METHODS: Analyses were based on data from the French nationwide ELFE birth cohort. Data on breastfeeding (BF) and complementary feeding (CF) were collected monthly from 2 to 10 months. Infant feeding practices were characterized using principal component analyses (PCA) and hierarchical ascendant classification. BMI z-score was computed at 1, 2, 3, 5 and 7.5 years, from data collected in the child's health booklet; 7.5-year overweight was defined according to IOTF references. Associations between infant feeding practices and BMI were investigated by linear regression models adjusted for main confounders.
RESULTS: Ever breastfeeding was not associated with BMI up to 7.5 years. Compared to intermediate breastfeeding duration (1 to <3 months), longer breastfeeding duration (≥6 months) was related to lower 1-year BMI, but not at older ages. Compared to the recommended age at CF introduction (4-6 months), early CF (<4 months) was related to higher BMI up to 5 years with a similar trend at 7.5 years, but not to the risk of overweight. The PCA patterns characterized by early baby cereal introduction and late food pieces introduction or by frequent intake of main food groups were related to a lower BMI up to 7.5 years.
CONCLUSION: Breastfeeding was related with a lower BMI in infancy but not thereafter, whereas an early CF initiation (<4 months) was associated with a higher BMI in childhood.
This is a single centre, non-randomized, open label one arm pilot study of Sorafenib 400 mg twice daily given for 12 weeks preoperatively in patients with advanced metastatic kidney cancer scheduled for cytoreductive surgery. Patients will be fully staged for disease progression with Brain MRI, CT, whole body Bone Scans, Kidney ultrasound and biopsy. Additionally, patients' cardiac status will be evaluated pre-enrolment with an ECG and MUGA Scan. Once enrolled into the study, patients will have clinic visits on weeks 2, 8 and 12 for monitoring visits with vital signs and adverse event recording plus blood evaluations for hematology and chemistry. Patients will be called on weeks 3,5,6,7,9,10 and 11 to determine any changes in health status. Surgery will occur at week 13, after a one week washout from study drug. Patients will resume on study drug 6 weeks post operatively (or later, if wound is not completely healed). Patients will continue on study drug and will be monitored every 4 weeks until disease progression, as determined by bone imaging and CT.
An antigen-binding protein targeting CD22 and a use thereof. In particular, the present invention relates to a chimeric antigen receptor comprising the antigen-binding protein and an application thereof. The chimeric antigen receptor comprises a targeting moiety, the targeting moiety comprises HCDR3, and HCDR3 comprises the amino acid sequence as set forth in SEQ ID NO:48. Also provided is a cell comprising or expressing the chimeric antigen receptor. The antigen-binding protein binds to a CD22 protein with a K D  value of about 2E-08 M or less. The chimeric antigen receptor may specifically bind to the CD22 protein.
A system includes a processor circuit that receives first external imaging data for a first region of a heart of a patient, the first region being associated with a first blood vessel having an occlusion. The processor circuit determines a first measurement indicative of blood flow through the first region. The processor circuit receives second external imaging data for a second region of the heart, the second region being associated with a second vessel of the heart lacking an occlusion. The processor circuit determines a second measurement indicative of blood flow through the second region. The processor circuit determines a progress of reperfusion therapy associated with the first region. The processor circuit outputs a visual representation of the progress to a display. To determine the progress, the processor circuit determines a parameter indicative of relative blood flow between the first region and the second region based on the first measurement and the second measurement.
Fourth-grade students at 5 elementary schools were recruited to participate. At each participating school, two fourth-grade classes were assigned to the CBBS intervention group and other two fourth-grade classes were assigned to the control group. The students in the intervention group received two, 30-min CBBS physical education (PE) lessons taught by the physical education teacher who were trained in implementation of the two CBBS lessons per week for 16 weeks. In contrast, the students in the control group received regular two PE lessons per week for 16 weeks taught by the other physical education teacher who were not be involved in the CBBS intervention training. All participating students who returned their parent/guardian' signed consent form were pre-tested and post-tested (immediately after the 16-week intervention) in cognitive functions and aerobic fitness. Descriptive statistics and linear mixed models were performed to analyze the data. All data analysis were conducted in Physical Activity and Health Lab of the School of Kinesiology at University of Michigan
Group B (Post facilitation stretch) static stretching exercises for the low back (plantar fascia, gastrocnemius, hamstrings, and erector spinae). Static stretching involved 3 sets of 3 repetitions for each muscle with a 30-second hold and 30-second rest interval for each repetition.
Pamidronatdinatrium 1 mg/kg max 60 mg for 3 days every 3 month in total of 3 series (0,3,6 month). First day first series 0,5mg/kg max 30 mg.
REGRANEX is for topical use; it is not for oral, ophthalmic or intravaginal use.

The amount of REGRANEX to be applied depends upon the size of the ulcer area. To calculate the length of gel to apply to the ulcer, measure the greatest length of the ulcer by the greatest width of the ulcer in either inches or centimeters. To calculate the length of gel in inches, use the formula shown below in Table 1, and to calculate the length of gel in centimeters, use the formula shown below in Table 2. 

Using the calculation, each square inch of ulcer surface will require approximately 2/3 inch length of gel squeezed from a 15 g tube. For example, if the ulcer measures 1 inch by 2 inches, then a 1 1/4 inch length of gel should be used for 15 g tubes (1 × 2 × 0.6 = 1 1/4).

Using the calculations for ulcer size in centimeters, each square centimeter of ulcer surface will require approximately a 0.25 centimeter length of gel squeezed from a 15 g tube. For example, if the ulcer measures 4 cm by 2 cm, then a 2 cm length of gel should be used for a 15 g tube [(4 × 2) ÷ 4 = 2].

The amount of REGRANEX to be applied should be recalculated by the physician or wound caregiver at weekly or biweekly intervals depending on the rate of change in ulcer area. The weight of REGRANEX from 15 g tubes is 0.65 g per inch length and 0.25 g per centimeter length.

To apply REGRANEX, the calculated length of gel should be squeezed on to a clean measuring surface, e.g., wax paper, and measured to the correct length with a ruler. The measured REGRANEX is transferred from the clean measuring surface using an application aid and then spread over the entire cleaned ulcer area to yield a thin continuous layer of approximately 1/16 of an inch thickness. The site(s) of application should then be covered by a saline moistened gauze dressing and left in place for approximately 12 hours. The dressing should then be removed and the ulcer rinsed with saline or water to remove residual gel and covered again with a moist primary dressing (without REGRANEX gel) for the remainder of the day. REGRANEX should be applied once daily to the ulcer until complete healing has occurred. If the ulcer does not decrease in size by approximately 30% after 10 weeks of treatment or complete healing has not occurred in 20 weeks, continued treatment with REGRANEX should be reassessed. The step-by-step instructions for applying REGRANEX in a home care setting can be found in the FDA-approved Instructions for Use.
Baclofen injection is a muscle relaxant and antispastic. Baclofen's pharmacological class is a gamma-aminobutyric acid (GABA)ergic agonist. Baclofen's chemical name is 4-amino- 3-(4-chlorophenyl) butanoic acid, and its structural formula is:

Baclofen

Baclofen is a white to off-white powder, with a molecular weight of 213.66. It is slightly soluble in water, very slightly soluble in methanol and ethanol, practically insoluble in acetone and ether, soluble in 0.1N hydrochloric acid, 0.1N sodium hydroxide, and insoluble in chloroform.

Baclofen injection is a sterile, pyrogen-free, isotonic solution free of antioxidants, preservatives or other potentially neurotoxic additives indicated only for intrathecal administration. The drug is stable in solution at 37°C and compatible with CSF. Each mL of baclofen injection contains baclofen USP 500 mcg, 1,000 mcg or 2,000 mcg and sodium chloride 9 mg in Water for Injection; pH range is 5.5 to 7.5.
FIELD: organic chemistry, peptides, medicine, pharmacy. SUBSTANCE: invention relates to agonist of ApoA-I including peptide or peptide analogue comprising from 15 to 29 amino acid residues that forms amphipathic α-helix in the presence of lipids and that is characterized by the following formula:   or its pharmaceutically acceptable salt. Values of radicals see in the invention claim. Compounds show high agonistic activity with respect to apolipoprotein A-I and can be used for treatment of diseases associated with dyslipoproteinemia including hypercholesterolemia, cardiovascular diseases, atherosclerosis, restenosis and septic shock. Invention describes multiple agonist of ApoA-I, complex of agonist of ApoA-I and lipid, pharmaceutical compositions comprising compounds proposed and method for treatment using agonists of ApoA-I. EFFECT: valuable medicinal properties of agonists. 62 cl, 18 tbl, 31 dwg
BACKGROUND: Laminin subunit gamma-1 (LAMC1) is a major extracellular matrix molecule involved in the tumor microenvironment. Knowledge of the biological features and clinical relevance of LAMC1 in cancers remains limited.
METHODS: We conducted comprehensive bioinformatics analysis of LAMC1 gene expression and clinical relevance in pan-cancer datasets of public databases and validated LAMC1 expression in glioma tissues and cell lines. The association and regulatory mechanism between hypoxia inducible factor-1α (HIF-1α) and LAMC1 expression were explored.
RESULTS: LAMC1 expression in most cancers in The Cancer Genome Atlas (TCGA) including glioma was significantly higher than that in normal tissues, which had a poor prognosis and were related to various clinicopathological features. Data from the Chinese Glioma Genome Atlas also showed high expression of LAMC1 in glioma associated with poor prognoses. In clinical glioma tissues, LAMC1 protein was highly expressed and correlated to poor overall survival. LAMC1 knockdown in Hs683 glioma cells attenuated cell proliferation, migration, and invasion, while overexpression of LAMC1 in U251 cells leads to the opposite trend. Most TCGA solid cancers including glioma showed enhancement of HIF-1α expression. High HIF-1α expression leads to adverse prognosis in gliomas, besides, HIF-1α expression was positively related to LAMC1. Mechanistically, HIF-1α directly upregulated LAMC1 promotor activity. Hypoxia (2% O2)-treated Hs683 and U251 cells exhibited upregulated HIF-1α and LAMC1 expression, which was significantly attenuated by HIF-1α inhibitor YC-1 and accompanied by attenuated cell proliferation and invasion.
CONCLUSIONS: High expression of LAMC1 in some solid tumors including gliomas suggests a poor prognosis. The hypoxic microenvironment in gliomas activates the HIF-1α/LAMC1 signaling, thereby promoting tumor progression. Targeted intervention on the HIF-1α/LAMC1 signaling attenuates cell growth and invasion, suggesting a new strategy for glioma treatment.
The invention belongs to the technical field of biology, and particularly relates to application of a Caninin 1.1/1.9 combined anti-CD47 antibody in preparation of a medicine for treating melanoma. The amino acid sequence of the Caninin 1.1 is shown as SEQ ID NO. 1; the amino acid sequence of the Caninin 1.9 is shown as SEQ ID NO. 2. The invention can make B16 cells apoptosis and promote B16 cells to express CD47, and in the presence of anti-CD47 antibody, promote macrophages to phagocytose tumor cells, and improve the curative effect of the calerin 1.1/1.9, which is also superior to that of singly using anti-CD47 antibody, thus laying foundation for expanding the application of CD47 inhibition/blocking drugs. The Caninin 1.1/1.9 provided by the invention can be combined with an anti-CD47 antibody and a therapeutic vaccine, so that 50% of tumor-bearing mice can completely remove tumors.
PURPOSE:To provide an effectively usable collagen film free from the isolation of silver, thereby securing safety and holding the strong antibacterial performance for a long period by allowing the collagen film to contain the silver carrying ceramic. CONSTITUTION:A collagen film contains the silver carrying ceramic in the film. In order to allow the collagen to contain the silver carrying ceramic in a dispersed form, collagen is suspended in the distilled water or a buffer solution, and the silver carrying ceramic in a finely pulverized form are added thereto and absorption fixed on the collagen through the violent stirring. Since the collagen is a protein, the collagen fixes ceramic firmly, and the ceramic does not slip off even after washing. The fixed ceramic quantity is adjusted by adjusting the particle size and quantity of the ceramic and the agitation time, and the antibacterial power is made proportional to the carrying quantity. If the fixed ceramic quantity is too much, the collagen film is made hard, while too less, the antibacterial power is reduced.
Methods and agents for suppressing expression of a mutant allele of a gene a nd providing a replacement nucleic acid are provided. The methods of the invention provide suppression effectors such as, for example, antisense nucleic acids, ribozymes, or RNAi, that bind to the gene or its RNA. The invention further provides for the introduction of a replacement nucleic aci d with modified sequences such that the replacement nucleic acid is protected from suppression by the suppression effector. The replacement nucleic acid i s modified at degenerate wobble positions in the target region of the suppression effector and thereby is not suppressed by the suppression effector. In addition, by altering wobble positions, the replacement nucleic acid can still encode a wild type gene product. The invention has the advantage that the same suppression strategy could be used to suppress, in principle, many mutations in a gene. Also disclosed is a transgenic mouse th at expresses human rhodopsin (modified replacement gene) and a transgenic mouse that expresses a suppression effector targeting rhodopsin. Also disclosed in intraocular administration of siRNA.
BACKGROUND: Obesity is an increasing health concern, affecting 39% of the population. In Qatar, in recent years, the obese population contributed 35.9% of men and 46.1% of women. Qatar's obesity prevalence is higher in the region. The diet, rich in animal protein, high in oxalate, low in calcium, and the dry subtropical desert climate are risk factors for urolithiasis in Qatar. Objectives were the efficacy of percutaneous nephrolithotomy in obese patients. Patients and.
METHODS: We retrospectively reviewed the patients who underwent PCNL between January 2015 and December 2019. A total of 150 patients were enrolled. The patients were categorized into two groups according to BMI: <30 kg/m2 (group 1, non-obese) and >30 kg/m2 (group 2, obese). The stone clearance rate, operation time, duration of hospital stays, Postoperative analgesic use, and postoperative complications were compared among groups. The chi-square test was used to analyze variables and Complications were graded according to the Clavien-Dindo classification system.
RESULTS: The BMI values of 110 patients were lower than 30 kg/m2, while 40 patients' BMI values were higher than 30 kg/m2. There was no significant difference between operation time, fluoroscopy time, number of access points, or access sites when the two groups were compared. No significant difference was found in the total length of hospital stay, haemoglobin drop, or complication rates. Immediate stone-free rates were 81.8% in the non-obese group and 75% in the obese group (p=0.21).
CONCLUSIONS: In a retrospective study of 150 patients undergoing supine PCNL, the efficacy was not different between non-obese and obese patients. This is the first study evaluating these outcomes for PCNL performed under the ERAS protocol in the supine position. Further multicenter and prospective studies are required to verify these findings.
BACKGROUND: Hemophilia A patients are treated with factor (F) VIII prophylactically to prevent bleeding. In general, dosage and frequency are based on pharmacokinetic measurements. Ideally, an alternative dose adjustment can be based on the hemostatic potential, measured with a thrombin generation assay (TGA), like the Nijmegen hemostasis assay.
OBJECTIVE: The objective of this study was to investigate the predicted performance of a previously developed pharmacokinetic-pharmacodynamic model for FVIII replacement therapy, relating FVIII dose and FVIII activity levels with thrombin and plasmin generation parameters.
METHODS: Pharmacokinetic and pharmacodynamic measurements were obtained from 29 severe hemophilia A patients treated with pdVWF/FVIII concentrate (Haemate P®). The predictive performance of the previously developed pharmacokinetic-pharmacodynamic model was evaluated using nonlinear mixed-effects modeling (NONMEM). When predictions of FVIII activity or TGA parameters were inadequate [median prediction error (MPE) > 20%], a new model was developed.
RESULTS: The original pharmacokinetic model underestimated clearance and was refined based on a two-compartment model. The pharmacodynamic model displays no bias in the observed normalized thrombin peak height and normalized thrombin potential (MPE of 6.83% and 7.46%). After re-estimating pharmacodynamic parameters, EC50 and Emax values were relatively comparable between the original model and this group. Prediction of normalized plasmin peak height was inaccurate (MPE 58.9%).
CONCLUSION: Our predictive performance displayed adequate thrombin pharmacodynamic predictions of the original model, but a new pharmacokinetic model was required. The pharmacodynamic model is not factor specific and applicable to multiple factor concentrates. A prospective study is needed to validate the impact of the FVIII dosing pharmacodynamic model on bleeding reduction in patients.
PURPOSE:To discover lung cancer patients, by a method wherein an anti-human lung cancer specific monoclonal antibody ALC-1 is labelled with oxygen to be bonded to a lung cancer antigen and the amount of the second antibody bonded is assayed by measuring the activity of the label oxygen. CONSTITUTION:An ALC-1 (10mug/ml) is applied to an EIA plate with 96 holes at the rate of 100mul per hole, allowed to stand at 4 deg.C overnight and the plate is washed by PBS. Then, 1% BSA-PBS is applied to the plate at the rate of 200mul per hole allowed to stand overnight and the plate is washed thoroughly by PBS. Thereafter, normal human serum (25 samples) and serum of lung cancer patients (34 samples) are applied to the plate at the rate of 100mul per hole, allowed to stand at 4 deg.C overnight and then, the plate is washed thoroughly by PBS. Then, biotinated anti-lung cancer monoclonal antibody ALC-1 (10mug/ml) is applied to the plate as the second antibody at the rate of 100mul per hole, allowed to stand at the room temperature for 1hr and it is washed by PBS. Then, ABTS substrate liquid is applied thereto at the rate of 100mul per hole to be brought into a reaction at the room temperature for 30min. and a 5% SDS solution is applied thereto at the rate of 100mul per hole. Then, the relation is stopped. As a result, in the serum of lung cancer patients 14 out of 34 cases were positive cases with OD415 exceeding 0.4.
PURPOSE:A diuretic comprising a tumor necrosis factor or a tumor necrosis factor-like substance as an active ingredient. CONSTITUTION:A diuretic a tumor necrosis factor (TNF) polypeptide derived from human, having an amino acid sequence shown by the formula, a polypeptide (e.g., polypeptide lacking in 4-5 amino acid residue from N end group) having a diuretically active site, or its peptide salt as an active ingredient. An administration form is preferably parenteral administration. A dose is 10-600mug/kg, preferably 20-200mug/kg/day. In manufacturing a pharmaceutical preparation, a solution or a lyophilized preparation is preferable. In the manufacturing, the preparation is preferably blended with an excipient and a stabilizer (e.g., alubumin, globulin, etc.). Oral administration is possible by selecting a target substance and by invention in pharmaceutical preparation.
Pyrogenic polysaccharides derived from gramnegative bacteria are acylated, e.g. with an organic acid anhydride.  The dried bacteria containing such polysaccharides and preextracted with a solvent for lipoids may replace the polysaccharides themselves. The products are stated to be useful as stimulating agents for the pituitary-adreno-cortical system with only very negligible p side-effects.  To minimise side-effects, acylation should continue for at least five hours.  Examples describe the treatment of a pyrogenic coli polysaccharide with acetic or propionic anhydride in pyridine and water or in pyridine and formamide, and also the extraction of coli bacteria with chloroform and ethanol, acylation with acetic anhydride in pyridine and water, and further extraction with chloroform and ethanol.  Polysaccharides from other bacteria than coli bacteria are referred to.